Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

390 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.
Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G. Gombos A, et al. Among authors: gebhart g. NPJ Breast Cancer. 2022 Mar 16;8(1):38. doi: 10.1038/s41523-022-00409-x. NPJ Breast Cancer. 2022. PMID: 35296682 Free PMC article. No abstract available.
Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial.
Azim HA Jr, Rothé F, Aura CM, Bavington M, Maetens M, Rouas G, Gebhart G, Gamez C, Eidtmann H, Baselga J, Piccart-Gebhart M, Ellis C, Vuylsteke P, Cure H, Domont J, Ferro A, Toral-Peña JC, de Azambuja E, Sotiriou C, Di Cosimo S, Ignatiadis M. Azim HA Jr, et al. Among authors: gebhart g. Breast. 2013 Dec;22(6):1060-5. doi: 10.1016/j.breast.2013.08.014. Epub 2013 Sep 20. Breast. 2013. PMID: 24060577 Free article. Clinical Trial.
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, Van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart M, Flamen P, Di Cosimo S. Gebhart G, et al. J Nucl Med. 2013 Nov;54(11):1862-8. doi: 10.2967/jnumed.112.119271. Epub 2013 Oct 3. J Nucl Med. 2013. PMID: 24092940 Free article. Clinical Trial.
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P. Gebhart G, et al. Ann Oncol. 2016 Apr;27(4):619-24. doi: 10.1093/annonc/mdv577. Epub 2015 Nov 23. Ann Oncol. 2016. PMID: 26598545 Free article. Clinical Trial.
N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging.
Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Larsimont D, Doumont G, Van Simaeys G, Goldman S, Flamen P, Ghanem G. Wimana Z, et al. Among authors: gebhart g. Oncotarget. 2017 Apr 10;8(34):56185-56198. doi: 10.18632/oncotarget.17015. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915583 Free PMC article.
390 results